Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.

Development projects newly approved in 2025 will generate approximately $9.8 million in Linkage fees to support affordable housing, and approximately $1.9 million in Linkage fees to support job ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...